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Abstract 
 
Background: Observational studies find use in many aspects of medical research. 
One such aspect is vaccine effectiveness. Human Papillomavirus (HPV) vaccination 
is being implemented since 2007 in several countries. HPV types 16 and 18 have 
proven to be responsible for the development of cervical cancer. The vaccination 
aims to reduce that impact on public health. After numerous clinical trials validating 
the vaccine‘s efficacy, it is necessary to assess its effectiveness by conducting 
observational studies. The STROBE statement (Strengthening the Reporting of 
Observational Studies in Epidemiology) checklist has been widely used to evaluate 
the reporting quality of observational studies over the past few years. 
Purpose: The aim of this study was to assess the reporting quality of observational 
studies of HPV vaccination in cervical cancer prevention, based on STROBE 
statement. 
Methods: A literature search was conducted in PubMed, resulting in seven eligible 
studies. The entire text of the studies was evaluated and scored, using STROBE 
statement. All 22 items/sub-items (32 in total) of STROBE were used for the 
evaluation. 
Results: 11 out of 32 items/sub-items, were reported in all seven studies, while 17 
out of 32 were reported in more than 70% of the studies. The best-written sections 
were Introduction and Discussion. The worst-written sections were the Results (3 in 
11 items in more than 70% of the studies) and Methods (6 out of 14 items in more 
than 70% of the studies). The total individual scores of studies varied from 80.6% to 
46.7%, with an average of 60.6% 
Conclusion:  The reporting quality of the eligible observational studies appears to be 
average to good, with some methodological problems common to all studies. It 
appears that improvements are necessary, in order to increase the credibility of 
observational studies. 
Keywords: STROBE, Human Papillomavirus, HPV, HPV 16/18, cervical cancer, 
observational studies, reporting quality.  
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1. INTRODUCTION 
 
Observational studies play a major part in medical research. [1] Case-control, 
cohort, cross-sectional studies and any other variation can find use in investigating 
the cause of diseases. Moreover, they can be more appropriate when searching for 
rare or late adverse effects of medical interventions [2] or when ethical issues occur, 
such as when searching the etiology of cancer. Observational studies are, also, less 
time and money consuming than randomized control trials [3]. 
Adequate reporting of studies is essential for readers to comprehend the results 
and validate the study as credible.  There is a number of checklists and guidelines 
that aim to improve the quality of various study designs [4], as well as observational 
studies [5]. The Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) is one of these checklists. Its use is recommended by 
numerous medical journals [2, 6, 7]. 
It consists of 22 criteria (items) that relate to the title, abstract, introduction, 
methods, results, and discussion sections of articles.  Checklists for all three major 
observational study designs (cohort, case-control, cross-sectional), as well as a 
combined checklist (appendix table), are available at http://www.strobe--
statement.org/. Out of the 22 items 18 are common to all three study designs, while 
four are design-specific, with different variations for each study design. 
Cervical cancer constitutes a major health issue world widely, being the third 
most common type of cancer among women [8]. The role of HPV as an etiologic 
agent of cervical cancer has been proved by several epidemiological and molecular 
studies [9, 10]. 
Human papillomavirus (HPV) is a non-enveloped double-stranded DNA virus, 
which belongs to the Papillomaviridae family [11]. More than 35 types of HPV have 
been identified in genital tract infections caused by sexual transmission [8], with the 
most common being 6, 11, 16 and 18. [9, 10] There is no evidence associating the 
first two types with the etiology of cervical cancer [8], thus they are considered low-
risk, unlike serotypes 16 and 18 which are considered high-risk. [9, 10] 
Non-infectious, adjuvanted vaccines have been developed to reduce the burden 
of HPV infection and related diseases. [10] The vaccines contain virus-like particles 
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(VLPs) for HPV types 16, 18, 6, and 11 (tetravalent) and for HPV types 18 and 16 
(bivalent) [10]. Two vaccines were commercialized in 2007 [12]. To date, HPV 
vaccination against HPV16 and HPV18 among HPV-naïve women has proved to be 
nearly 100% efficacious in preventing the incidence of related cervical precancerous 
lesions, for approximately 5–6 years after vaccination [13]. With undeniable evidence 
of efficacy, it is now the question of effectiveness that matters most [14]. Contrary to 
vaccine efficacy trials, population-based studies more likely to reflect the true 
vaccination impact on the population [14, 15]. It can be more accurately 
approximated in observational studies.  
The aim of this study is to critically evaluate the quality of observational studies 
investigating the effect of Human Papillomavirus (HPV) vaccines in cervical cancer 
prevention, with the use of STROBE statement. Seven eligible studies were identified 
and were evaluated using the entirety of the statement. 
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The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: 
Checklist of Items That Should Be Addressed in Reports of Observational Studies 
 
 
Title and abstract  
1 (a) Indicate the study’s design with a commonly used term in the title or the abstract. 
(b) Provide in the abstract an informative and balanced summary of what was done and what was found. 
 
Introduction 
Background/ rationale 2  
Explain the scientific background and rationale for the investigation being reported. 
Objectives 3  
State specific objectives, including any prespecified hypotheses. 
 
Methods 
Study design 4  
Present key elements of study design early in the paper. 
Setting 5  
Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection. 
Participants 6  
(a) Cohort study: Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up. 
Case–control study: Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the 
rationale for the choice of cases and controls. 
Cross-sectional study: Give the eligibility criteria, and the sources and methods of selection of participants. 
(b) Cohort study: For matched studies, give matching criteria and number of exposed and unexposed. 
Case–control study: For matched studies, give matching criteria and the number of controls per case. 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if  
applicable. 
Data sources/ measurement8 
 For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of 
assessment methods if there is more than one group. 
Bias 9  
Describe any efforts to address potential sources of bias. 
Study size 10  
Explain how the study size was arrived at. 
Quantitative variables 11  
Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why. 
Statistical methods 12  
(a) Describe all statistical methods, including those used to control for confounding. 
(b) Describe any methods used to examine subgroups and interactions. 
(c) Explain how missing data were addressed. 
(d) Cohort study: If applicable, explain how loss to follow-up was addressed. 
Case–control study: If applicable, explain how matching of cases and controls was addressed. 
Cross-sectional study: If applicable, describe analytical methods taking account of sampling strategy. 
(e) Describe any sensitivity analyses. 
 
Results 
Participants 13  
(a) Report the numbers of individuals at each stage of the study—e.g., numbers potentially eligible, examined for eligibility, confirmed 
eligible, included in the study, completing follow-up, and analyzed. 
(b) Give reasons for nonparticipation at each stage. 
(c) Consider use of a flow diagram. 
Descriptive data 14  
(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and 
potential confounders. 
(b) Indicate the number of participants with missing data for each variable of interest. 
(c) Cohort study: Summarize follow-up time—e.g., average and total amount. 
Outcome data 15  
Cohort study: Report numbers of outcome events or summary measures over time. 
Case–control study: Report numbers in each exposure category or summary measures of exposure. 
Cross-sectional study: Report numbers of outcome events or summary measures. 
Main results 16  
(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence intervals). 
Make clear which confounders were adjusted for and why they were included. 
(b) Report category boundaries when continuous variables were categorized. 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period. 
Other analyses 17  
Report other analyses done—e.g., analyses of subgroups and interactions and sensitivity analyses. 
 
Discussion 
Key results 18  
Summarize key results with reference to study objectives. 
Limitations 19  
Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of 
any potential bias. 
Interpretation 20  
Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results  from similar 
studies, and other relevant evidence. 
Generalizability 21  
Discuss the generalizability (external validity) of the study results. 
 
Other information 
Funding 22  
Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the 
present article is based. 
 
Appendix Table – STROBE statement (combined) www.strobe-statement.org 
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2. METHODS 
 
An online literature search was conducted in PubMed, from July 15th 2015 
until July 31st 2015. The search included the terms: ("HPV" or "human 
papillomavirus") and ("vaccine" or "vaccination") and ("cervical cancer" or "cervical 
lesions" or "cervical abnormalities" or "HPV 16/18") as free text and ―epidemiologic 
studies‖ as a MeSH Term. Eligibility Criteria included observational studies 
measuring HPV vaccine effectiveness (either 16/18 HPV type prevalence or cervical 
abnormalities diagnosed cytologically/histologically). Titles of all studies identified, 
were examined to determine possible eligibility for our study. Whenever a title 
appeared to be in line with our criteria, and evaluation of the studies‘ abstracts 
followed. In two cases there was the need to evaluate the entire text before exclusion 
from the assessment [16, 17] (Figure 1).  
Special consideration was taken for studies that used prediction models to 
estimate the impact of vaccination in the population. In the end, it was decided to 
completely exclude such studies, since their primary design‘s goal was calculation of 
HPV type prevalence. The application of computer-based models was conducted as 
an analysis, by implementing additional HPV vaccine trial data. Therefore, the 
addition of such publications in the study would cause diversity amongst the 
evaluated papers. 
One study‘s primary objective was to analyze the dynamics of HPV infection 
and relevant genital diseases, through time [24]. Nevertheless, it provided analysis 
on the relation of HPV 16 infection and vaccination, thus it was included in the 
analysis.  
All 22 items of the checklist were considered for the evaluation. Including the 
sub-items that is a total of 33 items/sub-items. Whenever an item did not apply for a 
study it was dismissed. In order to clarify whether an item is adequately reported in 
the articles, we took into account the guidance provided by the STROBE Explanation 
and Elaboration document [6]. Positive responses are marked as ‗yes‘, whereas 
negative as ‗no‘. To gain a positive response the item had to be reported in enough 
detail for the reader to avoid any misconceptions [3].  
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It needs to be stated that the STROBE statement provides recommendations 
and not a mandatory methodology [6]. Hence, there is not one standard scale for 
dictating the quality of a study.  
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PubMed identified 400 
studies 
Studies excluded by title: 
133 socialdemographic  
78 prevalence and/or distribution 
2 reviews and meta-analysis 
26 cervical screening and/or other 
diagnosis 
3 men related studies 
6 oral and/or anal infection/cancer 
17 HPV and cancer associations 
25 cost related studies 
19 vaccine trials 
4 immune response measurement 
10 methods/tactics/recommendations 
6 HIV related studies 
4 other type of cancer  
13 risk factors and/or predictors 
3 other conditions related 
1 therapy related 
11 other vaccine-related studies 
4 not in English 
 
35 potentially eligible studies 
 
Studies excluded after reading the 
abstract: 
12 vaccine trials 
2 HPV and cancer associations 
5 prevalence and/or HPV type 
distribution studies 
1 condylomata related study 
6 prediction model studies 
 
9 potentially eligible studies 
 
Studies eliminated after reading the 
full text: 
1 HPV prevalence and vaccine 
acceptance 
1 prediction model-based study 
7 eligible studies 
 
Figure 1- Flow diagram of the search process 
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3. RESULTS 
 
Out of the 400 publications resulted, 7 studies were considered eligible to 
proceed for the quality evaluation [18-24] (Table1). Main reasons for eliminating 
studies include irrelevant subject (such as socialdemographic-focused studies that 
investigate the knowledge, attitudes and acceptance of the vaccine), vaccine trials, 
strictly cost-related studies, pre-vaccination prevalence and HPV type distribution 
studies, studies that only dealt with the impact of cervical screening, studies that 
investigated risk factors, HIV or other condition related studies, diagnosis related 
studies, studies that dealt with other types of cancer etc (Figure 1).  
 
    3.1 Study Characteristics  
All the studies selected were population-based. Five of them used data 
linkage from national registries to gather sufficient information. Out of the total, three 
are described as cohort, three as cross-sectional and one as case-control. Two of 
them took place in Scotland, two in Germany, two in Australia and one in Denmark. 
Two were measuring the prevalence of carcinogenic HPV types 16/18 and six 
considered the outcome to be the diagnosis of cervical abnormalities. Five were 
published in 2014 and two in 2013. The reason for the existence of solely recent 
publications is the fact that the vaccine was commercialized in 2007 [12]. It should 
take a few years to collect viable information for an observational study to deduct a 
safe conclusion. Study characteristics for each paper are analytically described in 
Table 2. 
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Title 
 
First Author 
Reference-
Index number 
 
Introduction and sustained high coverage of the HPV bivalent 
vaccine leads to a reduction in prevalence of HPV 16/18 and 
closely related HPV types 
 
 
 
K. Kavanagh 
 
 
 
[18] 
 
 
Early Impact of Human Papillomavirus Vaccination on 
Cervical Neoplasia—Nationwide Follow-up of Young Danish 
Women 
 
 
 
Birgitte Baldur-
Felskov 
 
 
[19] 
 
Impact of a population-based HPV vaccination program on 
cervical abnormalities: a data linkage study 
 
 
 
Dorota M. Gertig 
 
 
[20] 
 
Reduction of low- and high-grade cervical abnormalities 
associated with high uptake of the HPV bivalent vaccine in 
Scotland 
 
 
 
K. G. J. Pollock 
 
 
[21] 
 
Effectiveness of quadrivalent human papillomavirus vaccine 
for the prevention of cervical abnormalities: case-control 
study nested within a population based screening 
programme in Australia 
 
 
 
Elizabeth Crowe 
 
 
[22] 
 
Human Papillomavirus prevalence and probable first effects 
of vaccination in 20 to 25 year-old women in Germany: a 
population-based cross-sectional study via home-based self-
sampling 
 
 
 
Yvonne Deleré 
 
 
[23] 
Prevalence of high-risk HPV types and associated genital 
diseases in women born in 1988/89 or 1983/84 – results of 
WOLVES 
 
Karl Ulrich Petry 
 
[24] 
Table 1 - Eligible Studies 
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Title 
 
Publication 
Date 
 
 
Magazine 
 
Country 
 
Study Design 
 
Primary Outcome (of 
interest) 
 
Additional 
information 
 
 
[18] 
 
 
2014 
 
British 
Journal of 
Cancer 
 
 
 
Scotland 
 
 
Cross-
sectional 
 
 
HPV16/18 prevalence 
 
 
Data linkage 
 
 
[19] 
 
 
2014 
 
 
JNCI J 
Natl 
Cancer 
Inst 
 
 
 
 
Denmark 
 
 
 
Cohort 
 
 
 
Atypia or worse/CIN 
 
 
 
Data linkage 
 
 
[20] 
 
 
2013 
 
BMC 
Medicine 
 
 
 
Australia 
 
Retrospective 
cohort 
 
Cervical 
abnormalities/cytology 
 
 
Data linkage 
 
 
[21] 
 
 
 
2014 
 
British 
Journal of 
Cancer 
 
 
 
Scotland 
 
 
Cohort 
 
 
CIN diagnosis 
 
 
Data linkage 
 
 
 
[23] 
 
 
 
2014 
 
 
 
BMJ 
 
 
 
Australia 
 
 
 
Case-control 
 
 
Cervical 
abnormalities/cytology 
Nested 
within 
population 
based 
screening 
program 
 
 
[24] 
 
 
2014 
 
BMC 
Infectious 
Diseases 
 
 
 
Germany 
 
Cross-
sectional 
 
 
HPV 16/18 
prevalence 
 
 
Population-
based 
 
 
[25] 
 
 
2013 
 
BMC 
Infectious 
Diseases 
 
 
 
Germany 
 
 
Cross-
sectional 
 
 
HPV16 infection/ 
CIN 
 
 
Population-
based 
Table 2 - Study Characteristics 
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Table 3 shows the overall results, concerning the frequency by which the 33 
total items/sub-items of STROBE statement are being reported. One items (16c) did 
not apply in any of the studies, therefore it was dismissed. 11 out of the 32 sub-items 
were reported in all of the studies, whereas 13 out of 32 were reported in more than 
85% of the studies and 17 out of 32 in more than 70% of the studies.  
It should be noted that the best-written section of the studies appears to be the 
Introduction, with all of the studies reporting both items of the statement. Next is the 
Discussion with 3 out of 4 items scoring 7/7.  
The worst-written section appears to be the Results with only 3 out of its 11 
items being reported in more than 70% of the studies and one being reported in all of 
the studies. Only 6 out of 14 items in Methods are answered in more than 70% of the 
studies. 
Less reported items in particular, include items 5 (as far as the reporting of 
dates in concerned) 12c and 14b that deal with missing data and item 16c, which is 
about the reporting of Attributable Risk Fraction.  
Individual scores of studies were 63.3% [18], 61.3% [19], 54.8% [20], 53.1% 
[21], 80.6% [22], 64.5% [23] and 46.7% [24], with an average of 60.6% 
 
A more precise elaboration of the results (by item) follows. 
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STROBE 
statement 
 
[18] 
 
 
[19] 
 
 
[20] 
 
[21] 
 
[22] 
 
[23] 
 
[24] 
 
Total 
 
Title and 
abstract 
        
1a No Yes No No Yes Yes No 3/7 
1b Yes Yes Yes Yes Yes Yes Yes 7/7 
 
Introduction 
 
 
 
       
2 Yes Yes Yes Yes Yes Yes Yes 7/7 
3 Yes Yes Yes Yes Yes Yes Yes 7/7 
 
Methods 
 
        
4 Yes Yes Yes No Yes Yes Yes 6/7 
5 No No No No No No No 0/7 
6a Yes Yes Yes Yes Yes No Yes 6/7 
6b - - - - - - -  
7 Yes Yes Yes Yes Yes Yes Yes 7/7 
8 Yes No Yes No Yes Yes Yes 5/7 
9 Yes No No No Yes No No 2/7 
10 Yes No No No No Yes No 2/7 
11 - - - Yes Yes Yes - 3/3 
12a Yes Yes Yes Yes Yes No No 5/7 
12b Yes Yes No Yes Yes No No 4/7 
12c No No No No No No No 0/7 
12d No Yes No No No No No 1/7 
12e Yes Yes No Yes Yes No No 4/7 
 
Results 
 
        
13a No No No No Yes Yes No 2/7 
13b No No No No Yes Yes No 2/7 
13c No No No No Yes Yes No 2/7 
14a No Yes Yes No Yes Yes Yes 5/7 
14b No No No No No No No 0/7 
14c - No Yes No - - - 1/3 
15 Yes Yes Yes Yes Yes Yes Yes 7/7 
16a No Yes Yes Yes Yes Yes No 5/7 
16b - - - - - - -  
16c No No No No No No No 0/7 
17 Yes Yes Yes Yes Yes Yes Yes 7/7 
 
Discussion 
 
        
18 Yes Yes Yes Yes Yes Yes Yes 7/7 
19 Yes Yes Yes Yes Yes Yes Yes 7/7 
20 Yes Yes Yes Yes Yes Yes Yes 7/7 
21 Yes No No Yes Yes No No 3/7 
 
Other 
information 
 
        
22 Yes Yes Yes Yes Yes Yes Yes 7/7 
Total 
(Percentage %) 
19/30 
(63.3 %) 
19/31 
(61.3%) 
17/31 
(54.8%) 
17/32 
(53.1%) 
25/31 
(80.6%) 
20/31 
(64.5%) 
14/30 
(46.7%) 
 
Table 3 - Scoring 
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3.2.1 Title and abstract  
1(a) Indicate the study’s design with a commonly used term in the title or the abstract. 
The study design was only clearly indicated in only three out of the seven 
studies (two in the title and abstract [23, 24] and one only in the abstract [17]). The 
remaining four studies (three data linkage studies as indicated in table 1) used the 
term cohort to describe a group of women with similar characteristics and not as a 
study design term. In fact, two of them are cross-sectional studies [19, 25]. This can 
potentially cause misunderstandings amongst readers who are not familiar with the 
alternative use of the term. Furthermore, it can potentially cause incorrect indexing in 
electronic databases [6]. 
(b) Provide in the abstract an informative and balanced summary of what was done 
and what was found. 
The abstract was well-structured in all the studies, providing clear sections 
including background/purpose, methods, results and conclusions [18-22, 24] (or in 
one case objectives, design, setting, participants, main outcome measures, results, 
conclusions [23]). Two studies included keywords [23,24]. The cause of this trend 
may be the recent publication dates (2013-2014) and the fact that several were 
published in similar magazines (as indicated in table 2). 
    3.2.2 Introduction 
Background/rationale 2 Explain the scientific background and rationale for the 
investigation being reported. 
The scientific background in a paper provides the necessary knowledge on the 
subject for the reader to comprehend its purpose [6]. All the studies fulfill the criteria 
for this item. It should be noted, that all papers citated other studies to emphasize 
their goals.  
Objectives 3 State specific objectives, including any prespecified hypotheses. 
All papers, at the end of the Introduction, mentioned the goals of the studies. 
One study [20] gave additional information for the advantages of the study design in 
regards with their goals.   
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    3.2.3 Methods 
Study design 4 Present key elements of study design early in the paper. 
They key elements of the study design are important for the reader to further 
evaluate the investigators course of action and the study‘s results [6]. In one study 
the key elements are provided at the end of the introduction [20] (and then again at 
the middle of the Methods section), but since it is within STROBE‘s recommendations 
[6] it scored positive in this item. Another paper [24] described itself as ‗prospective 
population-based surveillance study‘ and in ‗statistical analysis‘ it mentions that the 
paper is a representation of a one-time cross-sectional analysis. A third study [21] did 
not mention the study design used, even though it explained elements such as the 
surveillance program from which data derived and the data linkage process.  
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection. 
All studies adequately described settings and locations. The reports of the 
exact dates however, was not so accurate. One paper [24] did not provide any dates 
at all at the Methods section (they were mentioned in results). Another [21] provided 
very little information on dates as well. Two studies [19] and [18] mentioned follow-up 
periods (2 out of three cohort studies). Only one [23] provided recruitment dates, 
though this might be the case since it was the only study that did not derive its data 
from national registries. One paper [18] provided data collection dates, while another 
[20] merely stated study period without further explanation. Since, none of the studies 
covered all the necessary points for this item, they all scored negative. 
Participants 6 
 (a) Cohort study—Give the eligibility criteria, and the sources and methods of 
selection of participants. Describe methods of follow-up. 
Case-control study—Give the eligibility criteria, and the sources and methods of case 
ascertainment and control selection. Give the rationale for the choice of cases and 
controls. 
Cross-sectional study—Give the eligibility criteria, and the sources and methods of 
selection of participant. 
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Most studies described eligibility criteria, along with other information that fulfill 
the criteria of the item (on regards with their study design). All data linkage cohorts 
described in detail the linkage process.  
Only one study [23] did not explain eligibility, but it may be described 
elsewhere along with the sampling process, as it is part of a greater project. 
Nonetheless, in order to score positive in the statement the items have to be clearly 
stated in the text [3]. 
In the case-control study [22] it is explicitly explained the criteria upon which 
the cases and the controls were chosen. 
All cohort studies are data linkage studies as well, so the follow-up data were derived 
from national registries.  
(b) Cohort study—For matched studies, give matching criteria and number of 
exposed and unexposed. 
Case-control study—For matched studies, give matching criteria and the number of 
controls per case. 
None of the studies used matching. 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, 
and effect modifiers. Give diagnostic criteria, if applicable. 
All studies provided information on certain variables of interest, whether they were 
outcomes, exposures or potential confounders. It should be noted that some were 
better structured than the rest [20, 22] or provided more detailed information [19, 22]. 
After consideration, one study [21] scored negative in this item, mainly due to lack of 
information on diagnostic criteria. Also, none of the studies clearly defined any 
variables as effect modifiers.  
Data sources/Measurement 8 For each variable of interest, give sources of data and 
details of methods of assessment (measurement). Describe comparability of 
assessment methods if there is more than one group. 
The methods of measurement are described in detail in most studies. They 
stated the methods and criteria they based their diagnosis on, hence it can be 
concluded that all there are not any differences in the diagnoses of different groups 
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of patients. In two studies, however, the assessment methods were not described [19, 
21]. Both were linkage studies that received data from national registries and 
investigated histological and cytological diagnosis. Therefore, one cannot deny the 
possibility that multiple laboratories, possibly using different scales of grading, might 
have caused a differentiation in diagnosis. 
Bias 9 Describe any efforts to address potential sources of bias. 
Only two studies appear to mention at this point any efforts made for avoiding 
bias. [18, 22] The first [18], in particular, mentioned it when describing the sensitivity 
analysis in ‗statistical analysis‘.  
Study size 10 Explain how the study size was arrived at. 
Just two studies mentioned the calculations for the study size. One [18] 
calculated it on accounts of powers and the other [23] based of precision. In the rest 
of the studies it was implied that, since they are population-based, they used the 
entirety of the available population data for the age cohorts that they chose.   
Quantitative variables 11 Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were chosen and why. 
Only three studies mentioned qualitative variables [21, 22, 23]. All the 
numerical variables were distinct. These include age [22, 23], acceptability of 
practices (1 to 6 scale) [23], and deprivation score (1 to 5 scale) [21]. 
Statistical methods 12 
(a) Describe all statistical methods, including those used to control for confounding. 
All studies described the statistical methods of choice. These include z-test 
[18], logistic regression [18, 22], Poisson regression [19], Mann-Whitney U test [20], 
chi-square test [18, 23], Fisher‘s exact test [23] and Cox proportional hazards 
regression [19, 20]. In some cases, statistical methods were simply described as 
univariate or multivariate [23, 24]. Adjusting for confounders was clearly stated in four 
studies [18, 19, 21, 22]. Since the terms univariate and multivariate analysis are 
considered vague, the studies that addressed them [23, 24] received a negative 
score. 
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(b) Describe any methods used to examine subgroups and interactions. 
Four of the studies fulfill the criteria for this sub-item. Two [18, 21] mentioned 
the possible interactions taken into account. The third [19] described subset analysis 
and stratification. Stratification was described in the case-control study [22]. 
(c) Explain how missing data were addressed. 
None of the studies mentioned the absence of data. The readers are led to 
assume that due to the nature of most studies (population-based data linkage 
studies) there were no missing data. Nevertheless, since it is only an assumption and 
it is not clearly defined in the studies, all scored negative in the sub-item.  
(d) Cohort study—If applicable, explain how loss to follow-up was addressed. 
Case-control study—If applicable, explain how matching of cases and controls was 
addressed. 
Cross-sectional study—If applicable, describe analytical methods taking account of 
sampling strategy. 
All studies, but one [19], failed to score positive in this item.  In this cohort 
study it was described how loss of cytology follow-up was addressed, when 
analyzing the data. It was implied, though, that the patients did have a follow up 
examination by the gynecologist, but did not have a Pap test. However, it was 
decided to emphasize the difference in the data analysis compared with the other 
studies. Hence, the study scored positive in this sub-item.  
(e) Describe any sensitivity analyses. 
Sensitivity analysis is used to determine the consistency of the main results 
with those obtained with alternative analysis strategies or assumptions [25]. Four of 
the studies [18, 19, 21, 22] conducted sensitivity analyses. The procedure was 
described in more detail in the case-control study [22]. 
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    3.2.4 Results 
13 (a) Report numbers of individuals at each stage of study—eg. numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, completing 
follow-up, and analysed. 
(b) Give reasons for non-participation at each stage. 
(c) Consider use of a flow diagram. 
Only two of the studies [22, 23] mentioned the numbers of participants in each 
stage of the study. While the others stated the number of eligible women they did not 
provide additional information for the reader to follow the course of the study. 
Both studies provide detailed flow diagrams, in which they give explicit reasons for 
ineligibility at each stage of the study.  
Descriptive data 14 
(a) Give characteristics of study participants (eg. demographic, clinical, social) and 
information on exposures and potential confounders. 
Five studies [19, 20, 22-24] provided detailed characteristics of the study 
participants, in the form of a table. Out of the remaining two, only one [21] 
differentiated the age of the participants, hence it was not considered to provide 
adequate information.  
(b) Indicate number of participants with missing data for each variable of interest. 
Same as in the Methods section, there was no indication of missing data and 
since it was not clearly stated whether all the data were available for analysis, it was 
considered inadequate reporting. 
(c) Cohort study—Summarise follow-up time (eg, average and total amount) 
Out of the 3 cohort studies, one [20] mentioned details about follow-up time. In 
detail, there was mention about average and maximum follow-up years [20]. Another 
[19] mentioned the follow-up time period, in the methods, but without any additional 
details. 
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Outcome data 15 
Cohort study—Report numbers of outcome events or summary measures over time. 
Case-control study—Report numbers in each exposure category, or summary 
measures of exposure. 
 Cross-sectional study—Report numbers of outcome events or summary measures. 
All three cohorts discussed calculation of person-years. They also provided 
figures with rates [20, 21] and/or Hazard Ratios [19, 20].  
In the case-control study the summary measures of exposure were included in 
the table with the main results. 
The cross-sectional [18, 22, 24] studies provided tables with summary 
measures (prevalence).  
Main results 16 
(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and 
their precision (eg. 95% confidence interval). Make clear which confounders were 
adjusted for and why they were included. 
All studies, but three [18, 19, 24], provided adjusted as well as unadjusted 
estimates. One of them [19] mentioned that there was adjusting for socioeconomic 
variables, but since it was not statistically significant it was not included in the paper. 
Thus, since there was adequate information on how adjusting was managed, the 
study scored positive in the item. Another study [18] provided only the adjusted 
measures. Even though there was mention of unadjusted measures, only some of 
them were presented and all of them were excluded from the table given. Therefore, 
it was not considered well-defined and the paper scored negative. 
 (b) Report category boundaries when continuous variables were categorized. 
No continuous variables were used in any of the studies. All qualitative variables 
described in the studies were considered distinct (see item 11).  
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(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period. 
In one study [21], even though they presented relative risks and incidence 
rates, they did not provide absolute risk measures over a period of time. Two studies 
[19, 20] calculated Hazard Ratios. The remaining studies provided Odds Ratios. 
None of the studies calculated attributable risk fractions (or preventable fractions 
since the exposure of interest is the effectiveness of the vaccination).  
 Other analyses 17 Report other analyses done—eg. analyses of subgroups and 
interactions, and sensitivity analyses. 
In one paper [24], vaccination can be considered the additional analysis, since 
the study is described as descriptive. In another paper [19] there was additional 
analysis using other cut-points, but the results are not shown in the paper. A third 
study [20], provided additional information on cervical abnormality rates by age is 
provided. In two papers [21] and [22] there was explicit information on sensitivity 
analysis.  Another [18] provided sensitivity analysis along with a subgroup analysis, 
indicating the most common pairings of HPV types. In the last paper [23] there were 
several additional analyses, but none about the main outcome of interest (HPV 
prevalence on vaccinated and unvaccinated population). 
    3.2.4 Discussion 
Key results 18 Summarise key results with reference to study objectives. 
All the studies summarized their results in the beginning of the Discussion 
section. As advised in the STROBE Explanation and Elaboration document, the 
studies presented in the first paragraph a small summary of their major findings. 
Limitations 19 Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. Discuss both direction and magnitude of any potential 
bias. 
All the studies provided extensive text emphasizing potential limitations to their 
methodology. They pointed out possible bias and how it could have affected their 
results. Additional information to diminish the magnitude of the bias was also 
provided. In one paper [24], limitations were being discussed, but in regards with the 
study‘s ability to calculate measures of association over time, and not bias.  
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Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence. 
Most of the Discussion section in all studies was dedicated to the 
interpretation of the results. Objectives, limitations, multiplicity of analyses and similar 
studies were all taken into consideration in order to come to a safe and accurate 
conclusion about the studies‘ results. 
Generalisability 21 Discuss the generalisability (external validity) of the study results. 
Generalisability of the results was specifically addressed in three of the studies. 
The first [19] mentioned that their data, and therefore the results of their analysis 
were generalisable to other countries with high HPV vaccine uptake. The same case 
applied in the second [18], in which generelisability was addressed but not 
specifically named as such. The third [22] stated in limitations, that generalisability of 
their findings may be limited to other studies. Though this, as far as the validity of the 
study is concerned, may be negative it is positive for the readers‘ better 
understanding of the findings and how they can be applied in other situations. Hence, 
the item is scored positive.  
    3.2.5 Other information 
Funding 22 Give the source of funding and the role of the funders for the present 
study and, if applicable, for the original study on which the present article is based 
All the studies provided information about their funding, as it is required by 
journals to declare an absence of conflict of interests. [26, 27] 
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4. DISCUSSION 
 
The goal of this study was to evaluate the quality of observational studies 
investigating the effect of Human Papillomavirus vaccination to cervical cancer 
prevention. In total, 7 studies were selected. All the articles used were published in 
the time period 2013-2014, years after the STROBE statement became available 
online. Nevertheless, the overall quality of the studies is average to good, with 17 out 
of 32 items/sub-items being reported in more than 70%. This scoring might be harsh 
considering that several items have many different points and all of them had to be 
reported in enough detail in order to score positive. Still, there are several 
methodological gaps that may prevent the readers from assessing the validity of the 
studies, especially in the Methods and the Results sections.  
While the settings and locations of the studies were confirmed, the relevant 
dates were not explicitly described. In a paper about cancer studies [28], it was 
estimated that about 24% of 132 studies, using survival analysis, never mentioned 
the date on which follow-up ended. Moreover, all studies lacked mention of effect 
modifiers. Missing data was another issue, as none of the studies explained how they 
were handled in the analysis. There was not even as much as a mention of patients 
with missing data. In a similar study, assessing the quality of observational studies in 
cancer [3], it was found that only 23% of the studies explained how missing data was 
handled in the analysis, while only 31% mentioned the number of subjects with 
missing data. Furthermore, as it is the case in a great amount of other epidemiologic 
studies [30, 31], only two of the papers include sample size calculations. The same 
applies with addressing potential bias [31]. 
There is a number of limitations to our study. The search was conducted in 
only one database (PubMed) and used the ‗epidemiologic studies‘ Mesh term, which 
might have restricted the results. Nevertheless, this methodology was followed in 
similar studies [3, 29] with adequate and diverse results. Therefore, it is more 
probable that the limited number of eligible studies is due to the vaccine being 
commercialized in 2007. It takes years for cancerous lesions, which would 
demonstrate the effect of vaccination, to develop. Another limitation derives from the 
fact that there was only one evaluator assessing the studies. Since the term 
‗adequate‘ or ‗clearly reported‘ are up to a point subjective, the scores may differ 
between different evaluators. Adding to the fact that the STROBE statement is a list 
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of recommendations and not a scoring scale, one cannot compare the scores to that 
of other studies. The scoring criteria, however, remain the same for all the papers 
included in this study.  
In conclusion, this study emphasizes the continuous need for improvement on 
certain aspects of the reporting quality of observational studies, by assessing those 
addressing the effectiveness of HPV vaccination in cervical cancer prevention. 
  
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:52 EET - 137.108.70.7
26 
 
5. REFERENCES 
 
 
1. Glasziou P, Vandenbroucke JP, Chalmers I (2004) Assessing the quality of 
research. BMJ 328: 39–41. 
2. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. 
(2007) The Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) statement: guidelines for reporting observational studies. Lancet. 
2007;370:1453–1457. 
3. Papathanasiou AA, Zintzaras E. (2010) 
Assessing the quality of reporting of observational studies in cancer. Ann 
Epidemiol. 2010 Jan;20(1):67-73. doi: 10.1016/j.annepidem.2009.09.007. 
4. Vandenbroucke JP. (2009) Strega, STROBE, STARD, SQUIRE, MOOSE, 
PRISMA, GNOSIS, TREND, ORION, COREQ, QUOROM, REMARK. And 
CONSORT: for whom does the guideline toll? J Clin Epidemiol. 2009;62:594–596. 
5. Nijsten T, Spuls P, Stern RS. STROBE: a beacon for observational studies. Arch 
Dermatol. 2008;144:1200–1204 
6. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, 
et al. (2007) Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE): explanation and elaboration. PLoS Med. 2007;4:e297 
7. Knottnerus A, Tugwell P. (2008) STROBE- a checklist to strengthen the reporting 
of observational studies in Epidemiology. J Clin Epidemiol. 2008;61:393. 
8. Rey Ares L, Ciapponi A, Pichon-Riviere A. (2012) Efficacy and safety of human 
papilloma virus vaccine in cervical cancer prevention: systematic review and meta-
analysis. Arch Argent Pediatr. 2012 Dec;110(6):483-9. doi: 10.1590/S0325 
00752012000600005. 
9. Bosch FX, Manos MM, Munoz N, Sherman M, et al. (1995) Prevalence of human 
papillomavirus in cervical cancer: a worldwide perspective. International biological 
study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87(11):796-
802. 
10. Koutsky L. (1997) Epidemiology of genital human papillomavirus infection. Am J 
Med 1997;102(5A):3-8. 
11. Bernard HU, Burk RD, Chen Z, Van Doorslaer K, Zur Hausen H, de Villiers EM. 
(2010) Classification of Papillomaviruses (PVs) based on 189 pv types and proposal 
of taxonomic amendments. Virology.2010;401(1):70–9. doi: 
10.1016/j.virol.2010.02.002. 
12. Orlando G, Fasolo M, Mazza F, Ricci E, Esposito S, Frati E, Zuccotti GV, Cetin 
I, Gramegna M, Rizzardini G, Tanzi E; Valhidate Study Group. (2014) 
Risk of cervical HPV infection and prevalence of vaccine-type and other high 
risk HPV types among sexuallyactive teens and young women (13-
26 years) enrolled in the VALHIDATE study. Hum Vaccin 
Immunother. 2014;10(4):986-94. Epub 2014 Jan 15. 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:52 EET - 137.108.70.7
27 
 
13. Lu B, Kumar A, Castellsague X, Giuliano AR. (2011) Efficacy and safety of 
prophylactic vaccines against cervical HPV infection and diseases among women: a 
systematic review and meta-analysis. BMC Infect Dis 2011; 11:13. 
14. Castle PE, Zhao FH. (2011) Population effectiveness, not efficacy, should decide 
who gets vaccinated against human papillomavirus via publicly funded programs. J 
Infect Dis. 2011 Aug 1;204(3):335-7. doi: 10.1093/infdis/jir287. 
15. Weinberg  GA, Szilagyi  PG. (2010)  Vaccine epidemiology. J Infect Dis. 
2010;201(11):1607-1610. 
16. Agorastos T1, Chatzistamatiou K, Zafrakas M, Siamanta V, Katsamagkas 
T, Constantinidis TC, Lampropoulos AF; LYSISTRATA study group.  (2014) 
Epidemiology of HPV infection and current status of cervical cancer prevention in Gre
ece: final results of theLYSISTRATA cross-sectional study. Eur J Cancer Prev. 2014 
Sep;23(5):425-31. doi: 10.1097/CEJ.0000000000000060. 
17. Hibbitts S, Tristram A, Beer H, McRea J, Rose B, Hauke A, Nuttall D, Dallimore 
N, Newcombe RG, Fiander A.  (2014) 
UK population based study to predict impact of HPV vaccination. J Clin Virol. 2014 
Feb;59(2):109-14. doi: 10.1016/j.jcv.2013.12.002. Epub 2013 Dec 12. 
18. Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, Robertson 
C, Donaghy M. (2014) Introduction and sustained high coverage of 
the HPV bivalent vaccine leads to 
a reduction in prevalence of HPV16/18 and closely related HPV types. Br J 
Cancer. 2014 May 27;110(11):2804-11. doi: 10.1038/bjc.2014.198. Epub 2014 Apr 
15. 
19. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. (2014) 
Early impact of human papillomavirus vaccination on cervical neoplasia- 
nationwide follow-up of young Danishwomen. J Natl Cancer Inst. 2014 
Mar;106(3):djt460. doi: 10.1093/jnci/djt460. Epub 2014 Feb 19. 
20. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. (2013) 
Impact of a population-based HPV vaccination program on cervical abnormalities: 
a data linkage study. BMC Med. 2013 Oct 22;11:227. doi: 10.1186/1741-7015-11-
227. 
21. Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, Robertson 
C, Cruickshank M, Palmer TJ, Nicoll S, Donaghy M. (2014) Reduction of low- 
and high-grade cervical abnormalities associated with high uptake of 
the HPV bivalent vaccinein Scotland. Br J Cancer. 2014 Oct 28;111(9):1824-30. doi: 
10.1038/bjc.2014.479. Epub 2014 Sep 2. 
22. Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert 
SB, Whiteman DC. (2014) 
Effectiveness of quadrivalent human papillomavirus vaccine for 
the prevention of cervical abnormalities: case-control study nested within 
a population based screening programme in Australia. BMJ. 2014 Mar 4;348:g1458. 
doi: 10.1136/bmj.g1458. 
23. Deleré Y, Remschmidt C, Leuschner J, Schuster M, Fesenfeld M, Schneider 
A, Wichmann O, Kaufmann AM. (2014) 
Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:52 EET - 137.108.70.7
28 
 
 year-old women inGermany: a population-based cross-sectional study via home-
based self-sampling. BMC Infect Dis. 2014 Feb 19;14:87. doi: 10.1186/1471-2334-
14-87. 
24. Petry KU, Luyten A, Justus A, Iftner A, Strehlke S, Reinecke-Lüthge A, Grunwald 
E, Schulze-Rath R, Iftner T (2013) Prevalence of high 
risk HPV types and associated genital diseases in women born in 1988/89 or 1983/8
4--resultsof WOLVES, a population-based epidemiological 
study in Wolfsburg, Germany. BMC Infect Dis. 2013 Mar 13;13:135. doi: 
10.1186/1471-2334-13-135. 
 
25. Rothman KJ, Greenland S. (1998) Basic methods for sensitivity analysis and 
external adjustment. In: Rothman KJ, Greenland S, ed. Modern Epidemiology. 2nd 
ed. Philadelphia: Lippincott Raven; 1998:343-57. 
26. International Committee of Medical Journal Editors. (1997) Uniform requirements 
for manuscripts submitted to biomedical journals. N Engl J Med. 1997;336: 309-15. 
27. Krimsky S, Rothenberg LS. (2001) Conflict of interest policies in science and 
medical journals: editorial practices and author disclosures. Sci Eng Ethics. 2001; 
7:205-18.  
28. Altman DG, De Stavola BL, Love SB, Stepniewska KA. (1995) Review of survival 
analyses published in cancer journals. Br J Cancer. 1995;72:511-8.  
29. Sakai M, Kakutani S, Tokuda H, Suzuki T, Kominami M, Egawa K, Saito K, Rogi 
T, Kawashima H, Shibata H, Sasaki S, (2014) Arachidonic Acid and Cerebral 
Ischemia Risk: A Systematic Review of Observational Studies.. Cerebrovasc Dis 
Extra. 2014 Nov 5;4(3):198-211. doi: 10.1159/000367588. eCollection 2014 Sep-Dec. 
Review. 
30. Pocock SJ, Collier TJ, Dandreo KJ, de Stavola BL, Goldman MB, Kalish LA, et al. 
(2004) Issues in the reporting of epidemiological studies: a survey of recent practice. 
BMJ. 2004;329:883. 
31. Tooth L, Ware R, Bain C, Purdie DM, Dobson A. (2005) Quality of reporting of 
observational longitudinal research. Am J Epidemiol. 2005;161:280-8. 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:52 EET - 137.108.70.7
